Abstract:
Integrating Artificial Intelligence (AI) into drug discovery revolutionizes the pharmaceutical industry and transforms healthcare outcomes. This article explores the profound impact of AI across various stages of drug development, highlighting how it accelerates the process, enhances precision, reduces costs, and fosters innovation. Through case studies of companies like Insilco Medicine, DeepMind's Alpha Fold, and Benevolent AI, we illustrate AI's ability to identify new drug candidates, predict protein structures, and efficiently repurpose existing drugs. AI's role in advancing personalized medicine ensures treatments are tailored to individual genetic profiles, improving efficacy and reducing adverse effects. AI's cost-reducing potential also promises more affordable and accessible medications, particularly benefiting low- and middle-income countries. As AI continues to evolve, it is poised to bring about faster development cycles, increased investment in rare diseases, and a more equitable global healthcare system. This article underscores AI's transformative power in drug discovery, paving the way for a new medical era where innovative, effective, and personalized treatments are readily available to all.